PPARG and metabolic dysfunction-associated steatohepatitis: The rationale for its use in NASH includes the expected synergy of improved insulin resistance and increased lipid oxidation from its PPAR-γ and PPAR-α effects respectively, which would reduce the lipotoxic load to the liver24.